Navigation Links
Tobacco makes medicine
Date:3/18/2009

Tobacco isn't famous for its health benefits. But now scientists have succeeded in using genetically modified tobacco plants to produce medicines for several autoimmune and inflammatory diseases, including diabetes. The research is published in the open access journal BMC Biotechnology.

A large team of scientists from several European research organizations have participated in the study as part of the Pharma-Planta project (http://www.pharma-planta.org/). Led by Professor Mario Pezzotti at the University of Verona, they set out to create transgenic tobacco plants that would produce biologically-active interleukin-10 (IL-10), a potent anti-inflammatory cytokine. They tried two different versions of IL-10 (one from a virus, one from the mouse) and generated plants in which this protein was targeted to three different compartments within the cell, to see which would work most effectively.

The researchers found that tobacco plants were able to process both forms of IL-10 correctly, producing the active cytokine at high enough levels that it might be possible to use tobacco leaves without lengthy extraction and purification processes. The next step will be to feed the plants to mice with autoimmune diseases to find out how effective they are.

The authors are keen to use the plants to see whether repeated small doses could help prevent type 1 diabetes mellitus (T1DM), in combination with other auto-antigens associated with the disease. The team has a particular auto-antigen in its sights the 65-kDa isoform of the enzyme glutamic acid decarboxylase (GAD65) which they have also produced in transgenic tobacco plants.

According to Pezzotti, "Transgenic plants are attractive systems for the production of therapeutic proteins because they offer the possibility of large scale production at low cost, and they have low maintenance requirements. The fact that they can be eaten, which delivers the drug where it is needed, thus avoiding lengthy purification procedures, is another plus compared with traditional drug synthesis."


'/>"/>

Contact: Charlotte Webber
charlotte.webber@biomedcentral.com
44-207-631-9980
BioMed Central
Source:Eurekalert

Related biology news :

1. Does the desire to consume alcohol and tobacco come from our genetic makeup?
2. Scientists discover how cigarette smoke causes cancer: Study points to new treatments, safer tobacco
3. Your babys brain on drugs (and alcohol and tobacco)
4. UT researchers find link between advertising and increased tobacco use among Indias youth
5. Infection blocks lungs protective response against tobacco smoke
6. Novel bioreactor enhances interleukin-12 production in genetically modified tobacco plants
7. New drug makes weight loss safer
8. How mother of thousands makes plantlets
9. For honey bee queens, multiple mating makes a difference
10. Scientists spy enzyme that makes us unique
11. Thinking makes it so: Science extends reach of prosthetic arms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... 2016 Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring, and the ... five (5) year funding commitment by Securus to ... rehabilitation and reentry support to more inmates and ... 2004, the Prison Entrepreneurship Program (PEP) is an ...
(Date:11/30/2016)... 2016 Not many of us realize that we spend ? of our ... need to do it well. Inadequate sleep levels have been found to lead to ... and even cancer. Maybe now is the best time to rethink how ... to manage their sleep quality? Continue Reading ... ...
(Date:11/29/2016)... Nearly one billion matches per second with DERMALOG,s ... ... DERMALOG is Germany's largest Multi-Biometric ... Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's Fingerprint Identification System is ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... 8, 2016 Eutilex Co. Ltd. today announced ... $18.9M) Series A financing. This financing round included participation ... and SNU Bio Angel. This new funding brings the ... (US $27.7M) since its founding in 2015. ... development and commercialization of its immuno-oncology programs, expand its ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... phase I/II dose escalation and expansion clinical trial for its lead drug candidate, ... The purpose of the trial was to determine the safety, antitumor activity, and ...
(Date:12/7/2016)... Dec. 7, 2016 Neogen Corporation (NASDAQ: ... Dan Kephart as its chief science officer ... assume his responsibilities at Neogen effective Jan. 1. ... for the agribusiness unit of Thermo Fisher Scientific, as ... Life Technologies. His extensive industry experience also includes the ...
(Date:12/7/2016)... OTTAWA, Ontario , Dec. 7, 2016 /PRNewswire/ ... partnership with General Atomics (GA), welcome today,s award ... National Nuclear Security Administration (NNSA) of the Phase ... its project with Nordion and the University of ... Phase II funding will support the establishment of ...
Breaking Biology Technology: